Insights into the Rare-Ultra Orphan market & the challenges for manufacturers, providers, payers, pharmacies, and patients | NASP

Rare diseases affect nearly 10% of the US population and transformative changes to research and development, as well as modernized regulatory pathways, have accelerated the entry of orphan drugs to the market. This uptick has necessitated discussions on how best to manage these conditions to ensure the right therapy is provided to the right patient at the right time. This episode is a first step in creating an open and transparent dialogue on the challenges faced by insurers in a resource constrained healthcare environment. As the focus will offer listeners a view of the latest trends in rare disease / orphan drug market access, assessing current payer perspectives, and offering insights and potential implications of the management of rare disease and orphan drugs. By highlighting the key issues and opportunities, we hope that payers, providers, patients, and biopharmaceutical manufacturers will bridge the access gaps and ensure patients can receive medically necessary therapies to ultimately improve patient outcomes.